QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Allogene Therapeutics, Inc. (ALLO)

Healthcare

No action
Fundamental
2
Sentiment
3
Technical
1

Do Nothing: fundamentalScore is 2 (below the required floor of 3), which hard-blocks any long entry, and the chart independently offers no qualifying long — a pullback/oversold limit would be a countertrend bid (price 0.8387 below SMA50 1.41 with MACD line -0.15) while the breakout-stop alternative has no base at a 52-week low.

Analysis as of 2026-11-14· more than 2 trading days ago

Company overview

Allogene Therapeutics, Inc. is a clinical-stage company focused on developing genetically engineered allogeneic T-cell therapies for cancer treatment. Its key products include UCART19 for B-cell acute lymphoblastic leukemia and ALLO-501 for non-Hodgkin lymphoma. The company collaborates with several partners, including Pfizer and MD Anderson Cancer Center.

Fundamental

weak
Fundamental2
Weak fundamentals

Allogene's fundamentals are weak, characterized by negative cash flow and heavy dilution, offset by a strong liquidity position.

Pre-revenue clinical-stage allogeneic CAR-T developer with no product revenue and large operating losses (negative ROE/ROIC and deeply negative free cash flow), offset by $388.9 million of cash and investments, no debt facilities, no going-concern warning and a runway into Q1 2029. Heavy 2026 dilution (~51% share-count growth with $135 million of ATM capacity still open), a binary ALPHA3 clinical path, management turnover and negative DCF values produce an elevated-risk, weak-fundamentals profile in which the liquidity cushion is the principal mitigant.

Sentiment

fair
Sentiment3
Mixed / forming

Sentiment is mixed, with recent positive clinical data not yet impacting the stock price.

The dominant near-term driver is the first ALLO-329 Phase 1 RESOLUTION autoimmune dataset (announced, 2026-11-09), scored net-positive in both the first-party analyzer (+0.6) and third-party coverage (+0.5), set against a determinate improving sentiment delta (baseline polarity +0.035 → scoring polarity +0.267) and a Red-Flag Screen clean of both severe and moderate flags, so no red-flag cap applies. The setup nonetheless stays in the mixed/forming band because the anchoring catalyst is trailing and only partially priced with no forward-dated driver inside 30 days, and the equity tape has not confirmed the constructive press — the $0.8387 quote sits at the bottom of its $0.82–$4.46 52-week range.

Technical

very weak
Technical1
Confirmed downtrend

The stock is in a confirmed downtrend, trading at the low end of its range with no base for a breakout.

Chart quality 1/5: broken, high-conviction downtrend. Price 0.8387 sits below SMA20 (1.14), SMA50 (1.41), SMA200 (1.95), EMA9 (0.97), EMA21 (1.12), WMA9 (0.94), WMA21 (1.06), DEMA14 (0.88) and the 2026-11-13 daily VWAP (0.8408); only TEMA14 (0.85) is beneath spot. ADX14 at 46.04 and rising while price trades under the entire moving-average stack is trend strength pointing DOWN, not up. MACD is negative and expanding (-0.15 line vs -0.13 signal, histogram -0.02) on every one of the last four sessions. RSI14 23.48 and Williams %R -96.68 are deeply oversold, but oversold inside a waterfall is not a base — price is printing lower lows into the 52-week floor (0.82), tagged intraday on both 11-12 and 11-13. The tape is a failed-catalyst tape: the 2026-11-09 ALLO-329 Phase 1 release closed at 1.06 and the stock has been sold every session since (0.9319 → 0.9001 → 0.827), roughly -21% in four sessions on heavy distribution volume (22.9M shares on 11-10). ATR14 0.10 is 11.9% of price — the name has plenty of range, it is just using it to the downside. No constructive long structure exists: a pullback/oversold limit would be a countertrend bid (price < SMA50 with MACD < 0, and price < a declining SMA200 with no momentum reclaim), and a buy-stop breakout has no base — every settled overhead level (11-12 high 0.8969, 11-11 high 0.96) sits inside the falling EMA9/EMA21 stack, so structural risk would have to sit beneath the 0.82 low against ~2.0×ATR of reward. Layered on top, fundamentalScore is 2 (< 3), which is a hard block on any long entry regardless of the chart.

You’re looking at 2026-11-14 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.